Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense in Advanced CLL
NCT00021749Phase 2Completed
- Sponsor
- Genta Incorporated
- Start
- Jan 2001
- Primary completion
- Jan 2003
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in chronic lymphocytic leukemia (CLL), sponsored by Genta Incorporated. Started Jan 2001; status: completed.
02
Drugs
oblimersen
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00021749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021749.